| Outcome Measures: |
Primary: Number of participants with Adverse events (AEs) and Serious Adverse events (SAEs), Numbers of participants with AEs and SAEs including vital signs, electrocardiograms (ECG) and laboratory results, Part A: up to 12 weeks; Part B: up to 20 weeks | Secondary: Area Under Plasma Concentration-time Curve calculated to the end of a dosing interval (AUCtau) for MHS552, Characterize the AUCtau profile following multiple doses of MHS552, Part A: up to Day 78; Part B: up to Day 134|Maximum ObservBlood Concentrations (Cmax) for MHS552, Characterize the Cmax profile following multiple doses of MHS552, Part A: up to Day 78; Part B: up to Day 134|Time to Reach Maximum Blood Concentrations (Tmax) of MHS552, Characterize the Tmax profile following multiple doses of MHS552, Part A: up to Day 78; Part B: up to Day 134
|
